December 15th, 2014

Enantia appears in the section of Industry News of ALBA synchrotron newsletter (N. 38, December 2014), as it uses the facility to detect crystalline impurities in drug products.

Enantia collaborates with Pharmaceutical and Generic companies to identify and characterise different crystalline phases in drug substances and products. With an in-house X-Ray Diffractometer and carefully tailored experiments, the characterisation of the crystalline structure is possible. For challenging situations, for example when only a very small amount of sample is available, or the impurity appears in a minimum quantity, Enantia uses the Material Science and Powder Diffraction beamline at ALBA synchrotron to achieve the best possible characterization.

Read the full article